

# Claire F Friedman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8436376/publications.pdf>

Version: 2024-02-01

36  
papers

1,860  
citations

394421

19  
h-index

434195

31  
g-index

37  
all docs

37  
docs citations

37  
times ranked

3381  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2016, 2, 1346.	7.1	667
2	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2021, 22, 1290-1300.	10.7	178
3	Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. <i>JAMA Oncology</i> , 2018, 4, 98.	7.1	125
4	Combinatorial Cancer Immunotherapies. <i>Advances in Immunology</i> , 2016, 130, 251-277.	2.2	107
5	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5939-5947.	7.0	100
6	Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. <i>Cancer Medicine</i> , 2018, 7, 690-697.	2.8	90
7	Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw260.	6.3	56
8	Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. , 2020, 8, e001126.		54
9	Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial. <i>Gynecologic Oncology</i> , 2020, 159, 150-156.	1.4	43
10	Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. <i>Current Oncology Reports</i> , 2016, 18, 21.	4.0	39
11	Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 156, 194-202.	1.4	35
12	Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers. <i>Scientific Reports</i> , 2020, 10, 17769.	3.3	35
13	Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. <i>Cancer Discovery</i> , 2022, 12, 654-669.	9.4	34
14	Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. <i>Gynecologic Oncology</i> , 2019, 152, 251-258.	1.4	33
15	<i>BRCA</i> Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 665-679.	3.0	29
16	Checkpoint inhibition and melanoma: Considerations in treating the older adult. <i>Journal of Geriatric Oncology</i> , 2017, 8, 237-241.	1.0	27
17	Imaging findings of immune checkpoint inhibitor associated pancreatitis. <i>European Journal of Radiology</i> , 2020, 131, 109250.	2.6	24
18	Vitamin D Deficiency in Postmenopausal Breast Cancer Survivors. <i>Journal of Women's Health</i> , 2012, 21, 456-462.	3.3	22

#	ARTICLE	IF	CITATIONS
19	Options for Adjuvant Therapy for Uterine Leiomyosarcoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 7.	3.0	21
20	Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the SPY trial (CALGB 150007/150015/ACRIN6657). <i>Cancer Medicine</i> , 2014, 3, 693-701.	2.8	19
21	Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 161, 535-544.	1.4	16
22	Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. , 2022, 10, e003853.		16
23	Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 155, 51-57.	1.4	14
24	Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer. , 2015, 3, .		12
25	Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100852.	0.6	12
26	Atypical autoimmune adverse effects with checkpoint blockade therapies. <i>Annals of Oncology</i> , 2017, 28, 206-207.	1.2	11
27	A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers. <i>Gynecologic Oncology</i> , 2021, 160, 71-76.	1.4	9
28	Prevalence of psychotropic medication use among cosmetic and medical dermatology patients: A comparative study. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 416-419.	1.2	6
29	Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2021, 38, 100873.	0.6	5
30	Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2022-003430.	2.5	5
31	Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy. <i>Gynecologic Oncology</i> , 2020, 158, 303-308.	1.4	4
32	Pattern of disease and response to pembrolizumab in recurrent cervical cancer. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100831.	0.6	4
33	Managing Immunotherapy-related Side Effects. <i>Oncology &amp; Hematology Review</i> , 2015, 11, 143.	0.2	3
34	Patient-Physician Communication in the 21st Century. <i>Trends in Immunology</i> , 2016, 37, 347-349.	6.8	1
35	Vitamin D and Cancer—A Review. <i>US Endocrinology</i> , 2013, 09, 44.	0.3	0
36	305...Technical considerations for normalizing digital spatial profiling data with multiple within-patient samples. , 2020, , .		0